source
- AbbVie eyes pan-RAS market with up to $1.45 B option to acquire KestrelAbbVie announced it has signed an agreement that gives it the right to acquire Kestrel Therapeutics for up to $1.45 billion. The deal would give AbbVie access to Kestrel’s pipeline focused on pan-…
- Novartis CEO warns of impact from Germany's €60 billion healthcare spending cutsNovartis chief executive Vas Narasimhan said the company is very disappointed by Germany's proposal to reduce healthcare spending by more than €60 billion. He expressed concern that the cuts could…